Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

NCT01386580 is registered in ClinicalTrials.gov with BBB-Therapeutics B.V. as lead sponsor.

NCT NCT01386580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01386580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Lead sponsor
BBB-Therapeutics B.V.
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2011
Completion date
December 31, 2014
Enrollment
84 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, breast cancer, lung cancer, malignant glioma, melanoma